Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The company is banking on investors approving of its approach to harness exosomes, which had once been considered the cells’ garbage cans, as a means of pioneering a new class of biologic medicines.
Parnell Pharmaceuticals Holdings Ltd, a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, provides notice of its Annual General Meeting to be held Friday, 31 May 2019 at 9:00 a.m.
Polarean Imaging announces that the total number of shares in issue and total voting rights as at the date of this announcement is 101,435,933 ordinary shares of £0.00037 each.
Karolinska Development AB has published its Annual Report for 2018.
Ultragenyx Pharmaceutical Inc. announced that it will host a conference call on Monday, May 6, 2019 at 5pm ET to discuss first quarter 2019 financial results and provide a corporate update.
Auris Medical Holding Ltd. announced that its Board of Directors has approved a reverse stock split of its common shares at a ratio of 1-for-20.
Recipharm AB will publish its interim report for January-March 2019 on 3 May at 07:45 am CET.
Biom’up announced its full-year results for the year ending December 31, 2018, as approved by the Company’s Board of Directors on April 29, 2019, and provided an update on its operations.
Following the capital increase and listing on Nasdaq, cash and cash equivalents totaled €314.1 million as of March 31, 2019
UndergroundStocks.com, an elite wall street independent small cap media group with a history of bringing lucrative opportunities, Reports on Omni Health, Inc.